# A Long-Term Study on Safety of JNS001 in Adults With Attention-Deficit Hyperactivity Disorder

> **NCT01357993** · PHASE3 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 253 (actual)

## Conditions studied

- Attention-Deficit / Hyperactivity Disorder

## Interventions

- **DRUG:** JNS001

## Key facts

- **NCT ID:** NCT01357993
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 253 (ACTUAL)
- **Last updated:** 2014-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01357993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01357993, "A Long-Term Study on Safety of JNS001 in Adults With Attention-Deficit Hyperactivity Disorder". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01357993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*